Zl-2102 (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02397005 (ClinicalTrials.gov) | March 2015 | 27/2/2015 | Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects | Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects | Chronic Obstructive Pulmonary Disease;Asthma;Idiopathic Pulmonary Fibrosis | Drug: ZL-2102;Drug: Placebo matching ZL-2102 | Zai Lab Pty. Ltd. | NULL | Active, not recruiting | 18 Years | 45 Years | Male | 120 | Phase 1 | Australia |